Radiomics Model Distinguishes Gout Flares, May Improve Clinical Decision Making

Published Date: 13 Oct 2024

Radiomics Model Distinguishes Gout Flares, May Improve Clinical Decision Making

Read Full News

Latest News

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD

Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD

FDA News Recap: Novel Drug Approvals in Q2 2026

FDA News Recap: Novel Drug Approvals in Q2 2026

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

Why Has This Young Man Lost the Ability to Squat and Clench His Fists?

Joint stiffness is just one symptom of this rare debilitating inflammatory disease

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD

FDA News Recap: Novel Drug Approvals in Q2 2026

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

Joint stiffness is just one symptom of this rare debilitating inflammatory disease

News All Time

Acute Muscle Weakness and Skin Rash Following a Lupus Diagnosis

Clinicians consider many differentials

Optimizing the Diagnosis and Care of Sjögren's Disease: Real-World Perspectives From Patients and Clinicians

Optimizing the Diagnosis and Care of Sjögren's Disease: Real-World Perspectives From Patients and Clinicians

Evolving Frontiers in Systemic Lupus Erythematosus: Bridging Pathophysiology and Practice

Evolving Frontiers in Systemic Lupus Erythematosus: Bridging Pathophysiology and Practice

Competition Builds for Novel IgA Nephropathy Approach

Second agent targeting BAFF and APRIL appears effective in phase III trial

Care for Adults with Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Care for Adults with Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Don't Blame DMARDs for Adverse Drug Effects in Rheumatology Patients

Study finds most complaints arise from other meds such as antacids and antibiotics

Pictorial Tool Helps Lupus Patients Stay on Hydroxychloroquine

Decision aid clarifies benefits and risks; trial shows it improved adherence

Serology Affects Transition From Arthralgia to Full-Blown Rheumatoid Arthritis

ACPA status could inform treatment and preventive strategies

CAR T-Cell Trial in Rheumatoid Arthritis Starts Off Strong

Strong initial responses in 4 of 6 patients after many standard drugs had failed

Novel Biologic Performs Well in IgG4-Related Disease

Developers hope its dual mechanism will help it outdo the only currently approved therapy

Big Win for Secukinumab in Polymyalgia Rheumatica

Failed trial in giant cell arteritis also published the same day

Novel Concept, 'Immune Dimming,' Explored in Rheumatoid Arthritis

Pilot study finds partial B-cell depletion restores DMARD responsiveness

Late-Breaking Studies at EULAR Paint Rosy Picture of Rheumatology's Future

Psoriatic arthritis biologics square off, novel molecules and mechanisms, and old drugs made new
HTTP error: 503

Four-Year Data Confirm Anifrolumab Efficacy in Lupus

Study focuses on interferon blocker's hematologic and serologic benefits

Shingles Vaccine Might Be Less Effective in Systemic Sclerosis Patients

Prospective trial shows reduced immune response but no worsening of underlying disease

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot